Si Z, Hersey P
Oncology and Immunology Unit, Royal Newcastle Hospital, New South Wales.
Pathology. 1994 Jan;26(1):6-15. doi: 10.1080/00313029400169011.
Identification of antigens by monoclonal antibodies (MAbs) on sections of human melanoma by immunoperoxidase techniques was used to determine whether certain adhesion molecules and "selectin-like" molecules may be related to the metastatic potential of primary melanoma. The adhesion molecules examined were the leukocyte function antigen (LFA-1) and its ligand--intercellular adhesion molecule-1 (ICAM-1), the receptor alpha V beta 3 for vitronectin, its subunits alpha V and beta 3, and the CD36 receptor for thrombospondin (TSP). The criteria used to establish metastatic potential were relation of the molecules to tumor thickness and differences in expression: (i) between radial and vertical growth phases of the primary tumors and (ii) between 34 primary and 21 unrelated metastases. By these criteria ICAM-1, alpha V beta 3 and its subunit were associated with the malignant potential of primary melanoma. These molecules were not expressed on nevi or other skin cancers with low metastatic potential such as squamous (SCC) and basal cell carcinomas (BCC). In contrast, expression of TSP and the CD36 receptor for TSP were not related to metastatic potential. CD36 was expressed widely not only on melanoma but also on BCC, SCC and nevi. Similarly, the selectin-like molecule, CD44, was widely expressed on melanoma and non-melanoma carcinomas. The lymph node homing receptor, Leu 8, and the cutaneous lymphocyte antigen (CLA) were not detected on melanoma. Leu 8 was present on normal epithelium and SCCs, and common leucocyte antigen (CLA) was detected on lymphocytes in the epithelium and near melanoma. These results support previous suggestions that expression of ICAM-1 and V beta 3 integrin or its subunit beta 3 on melanoma may be a useful prognostic marker in primary melanoma. They do not support a role for CD44, Leu 8, CLA and TSP or its receptor CD36 in the metastatic process in melanoma.
采用免疫过氧化物酶技术，通过单克隆抗体（MAb）对人黑色素瘤切片上的抗原进行鉴定，以确定某些黏附分子和“类选择素”分子是否可能与原发性黑色素瘤的转移潜能相关。所检测的黏附分子包括白细胞功能抗原（LFA-1）及其配体——细胞间黏附分子-1（ICAM-1）、玻连蛋白受体αVβ3、其亚基αV和β3，以及血小板反应蛋白（TSP）的CD36受体。用于确定转移潜能的标准是分子与肿瘤厚度的关系以及表达差异：（i）原发性肿瘤的放射状生长阶段和垂直生长阶段之间；（ii）34例原发性肿瘤与21例无关转移瘤之间。根据这些标准，ICAM-1、αVβ3及其亚基与原发性黑色素瘤的恶性潜能相关。这些分子在痣或其他转移潜能低的皮肤癌如鳞状细胞癌（SCC）和基底细胞癌（BCC）中不表达。相比之下，TSP及其CD36受体的表达与转移潜能无关。CD36不仅在黑色素瘤上广泛表达，在BCC、SCC和痣上也广泛表达。同样，类选择素分子CD44在黑色素瘤和非黑色素瘤癌上也广泛表达。黑色素瘤上未检测到淋巴结归巢受体Leu 8和皮肤淋巴细胞抗原（CLA）。Leu 8存在于正常上皮和SCC中，上皮内及黑色素瘤附近的淋巴细胞上检测到普通白细胞抗原（CLA）。这些结果支持了先前的推测，即黑色素瘤上ICAM-1和Vβ3整合素或其亚基β3的表达可能是原发性黑色素瘤有用的预后标志物。它们不支持CD44、Leu 8、CLA以及TSP或其受体CD36在黑色素瘤转移过程中发挥作用。
